Fact Source: Financial Supervisory Service (DART) / 2024-03-25
Disclosure Type: Major Management Matters Related to Investment Decisions
💡 3-Second Summary
Celltrion has obtained a positive recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for ‘CT-P39,’ its biosimilar of the reference drug Xolair, covering 30 European countries.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Product and Ingredient Name: Xolair biosimilar CT-P39 (ingredient name: Omalizumab)
- Target Diseases (Indications):
- Allergic asthma
- Chronic rhinosinusitis with nasal polyps
- Chronic spontaneous urticaria
- Submission and Positive Opinion Dates:
- Submission Date: April 24, 2023 (local time)
- CHMP Recommendation Date: March 21, 2024 (local time)
- Regulatory Body: Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)
- Scope of Recommendation: Positive recommendation secured for marketing authorization across 30 European countries.
- Expected Effects and Future Plans:
- The recommendation covers all indications approved for the reference drug, and the company expects to provide alternative treatment options to a broader patient population in the future.
- Following this CHMP positive opinion, Celltrion expects to obtain final marketing authorization from the European Commission (EC) in the near future.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Filing of Positive Opinion from Regulatory Panel: This disclosure officially registers that the regulatory process for CT-P39, initiated with the submission on April 24, 2023, has progressed with the acquisition of a positive recommendation for marketing authorization from the CHMP.
- Indication Alignment and Country Coverage: The recommendation covers all primary indications held by the reference drug—allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria—targeting 30 European nations.
- No Financial Performance Causes Specified: This disclosure focuses on the receipt of the regulatory advisory committee’s positive opinion. It does not contain information regarding commercialization timelines, financial forecasts, or concrete causes regarding historical financial performance.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion’s latest disclosure confirms that its Xolair biosimilar candidate, ‘CT-P39,’ has secured a positive recommendation for marketing authorization from the CHMP, an advisory panel under the European EMA. The filing records the acquisition of this recommendation across all approved indications of the reference drug in 30 European countries, with the company expecting to seek final marketing authorization from the European Commission (EC) as the next step.
For investors reviewing this announcement, the primary operational checkpoint is the ‘final marketing authorization decision by the European Commission (EC).’ While the company expresses expectations of obtaining the final clearance in the near future based on the CHMP recommendation, the exact timeline of the EC’s final decision and subsequent distribution structures are not determined or specified in the filing. Consequently, investors are advised to focus on verifying the official receipt of the final EC approval through subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was restructured and newly drafted based on the official submitted data from the Financial Supervisory Service (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
